StreetAlpha.app
Home › Stocks › EOLS

Evolus, Inc. (EOLS)

Healthcare
$6.52
▼ −6.86%
LAST CLOSE · NOV 20

Evolus sells Jeuveau and Evolysse injectable aesthetic treatments to licensed aesthetic practitioners. It last closed at $6.52 on Nov 20, down 6.86% on the day. The next earnings report for EOLS is expected around Tue, Mar 2, 2027, after the close. For the quarter ended Sep 2026, EOLS reported EPS of -$0.19 on revenue of $78.0M, with revenue up 13.0% from a year ago. Over its last 8 reports the stock moved an average of 16.0% the session after earnings. Over the last 12 months EOLS insiders bought $0 of stock on the open market and sold $1.8M, according to SEC Form 4 filings.

AI Auto Pilots
Is EOLS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold EOLS.

Key Stats

Last 12 months
Results
Revenue
$325.5M
+13.9% vs a year ago
Net income
−$31.1M
−9.6% margin
EPS (diluted)
−$0.48
Free cash flow
−$4.9M
−1.5% margin
Valuation
Market cap
$431.5M
66.2M shares
P/E
–
No P/E while losing money
Price to sales
1.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$41.7M
At Sep 30
Debt
$156.9M
At Sep 30
Shareholder equity
−$37.8M
Shares outstanding
66.2M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $99.7M$99.7MFY2021FY2022: $148.6M$148.6MFY2022FY2023: $202.1M$202.1MFY2023FY2024: $266.3M$266.3MFY2024FY2025: $297.2M$297.2MFY2025

From EOLS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Mar 2
Estimated date · After the close
Reported EPS
-$0.19
Quarter ended Sep 2026
Year ago EPS
-$0.24
Same quarter last year
Revenue
$78.0M
+13.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.10Dec '24Mar 2025: -$0.30Mar '25Jun 2025: -$0.27Jun '25Sep 2025: -$0.24Sep '25Dec 2025: $0.00Dec '25Mar 2026: -$0.16Mar '26Jun 2026: -$0.12Jun '26Sep 2026: -$0.19Sep '26Latest -$0.19
Revenue by quarter
Dec 2024: $78.9MDec '24Mar 2025: $68.5MMar '25Jun 2025: $69.4MJun '25Sep 2025: $69.0MSep '25Dec 2025: $90.3MDec '25Mar 2026: $73.1MMar '26Jun 2026: $84.1MJun '26Sep 2026: $78.0MSep '26Latest $78.0M
How EOLS moved after its last 8 reports
Average move the session after a report ±16.0%
Nov 4, 2026After the close−9.0%
Aug 5, 2026After the close+19.9%
May 4, 2026After the close+14.2%
Mar 3, 2026After the close+35.4%
Jan 9, 2026Time not announced−1.6%
Nov 5, 2025After the close+5.4%
Aug 5, 2025After the close−28.5%
May 7, 2025After the close−14.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on EOLSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on EOLS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on EOLS

Technical Analysis

EOLS · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 9% below its 20 day and 14% below its 50 day average. It is 2% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 40). The nearest support is the swing low (Jun 11) at $6.46, and the nearest resistance the Pivot at $6.74.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 6.5%/day
Key levels
$9.3152 week high+42.8%
$7.4550 day average+14.3%
$7.41100 day average+13.7%
$7.1020 day average+8.9%
$6.97Pivot R1+6.9%
$6.75Swing high (May 28)+3.5%
$6.74Pivot+3.4%
$6.52Last close
$6.46Swing low (Jun 11)−0.9%
$6.42200 day average−1.5%
$6.28Pivot S1−3.7%
$3.8652 week low−40.8%
Indicators
RSI (14)40.11Middle of its rangeNeutral
MACD-0.19Below its signal lineBearish
Stochastic41.7Middle of its rangeNeutral
ADX (14)13.9No clear trend
Williams %R-83.7Oversold below −80, overbought above −20Oversold
CCI (20)-91.6Oversold below −100, overbought above 100Neutral
Rate of change−4.2%Change over 10 sessionsBearish
ATR (14)$0.43Typical daily range, 6.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for EOLS

What happened before

See how EOLS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow EOLS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How EOLS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for EOLSHow many large options trades hit EOLS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

EOLS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●83 buying vs 73 selling
  • ▼Held by funds -7.2 pts
  • ▲Funds holding +12
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding170158+7.6%
In funds' top 10220.0%
Held by funds76.6%83.8%−7.2 pts
New / increased31 / 5232 / 55−4.6%
Reduced / sold out53 / 2039 / 21+21.7%
Put/call ratio0.010.28−97.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See EOLS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

EOLS Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$1.8M7 sales · 2 insiders
48% of the selling was under pre-arranged trading plans.
2025-12 sold $92K2026-03 sold $797K2026-09 sold $950KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 2David MoatazediSee RemarksSale105,108$9.04$950K
Mar 20David MoatazediSee RemarksSale plan13,669$4.75$65K
Mar 20Rui AvelarSee RemarksSale3,119$4.75$15K
Mar 17Rui AvelarSee RemarksSale plan29,996$4.89$147K
Mar 17David MoatazediSee RemarksSale plan116,720$4.89$571K
Dec 22, 2025Rui AvelarSee RemarksSale plan2,261$7.15$16K
Every insider buy and sale for EOLS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See EOLS insider trades →

From SEC Form 4 filings by EOLS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EOLS is in one of them and how their past EOLS trades turned out.

EOLS in the AI portfolios
Loading…

EOLS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered EOLS in an article yet. Here's the latest on the wider market.

EOLS in the news

About Evolus

Evolus is a medical aesthetics company based in Newport Beach, California. It sells Jeuveau, an injectable botulinum toxin used to smooth frown lines, and Evolysse, a line of injectable hyaluronic acid gels used for wrinkles, folds, and facial volume. Its customers are licensed aesthetic practitioners, and patients generally pay for these treatments directly out of pocket rather than through insurance. The company relies on outside manufacturers in South Korea and France to produce its products.

Headquarters
Newport Beach, CA